Bionomics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Bionomics and buy or sell other stocks, ETFs, and their options commission-free!About BNOX
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.
CEOSpyridon Papapetropoulos, MD, PhD
CEOSpyridon Papapetropoulos, MD, PhD
Employees8
Employees8
HeadquartersBurlington, Massachusetts
HeadquartersBurlington, Massachusetts
Founded
Founded
Employees8
Employees8
BNOX Key Statistics
Market cap9.38M
Market cap9.38M
Price-Earnings ratio-0.17
Price-Earnings ratio-0.17
Dividend yield—
Dividend yield—
Average volume96.44K
Average volume96.44K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$21.40
52 Week high$21.40
52 Week low$2.77
52 Week low$2.77
Stock Snapshot
As of today, Bionomics(BNOX) shares are valued at $3.98. The company's market cap stands at 9.38M, with a P/E ratio of -0.17.
During the trading day, Bionomics(BNOX) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading volume for Bionomics(BNOX) stock has reached 0, versus its average volume of 96.44K.
Over the past 52 weeks, Bionomics(BNOX) stock has traded between a high of $21.40 and a low of $2.77.
Over the past 52 weeks, Bionomics(BNOX) stock has traded between a high of $21.40 and a low of $2.77.